SBIR-STTR Award

Staphylococcus aureus iron-regulated proteins as vaccine candidates
Award last edited on: 10/30/2009

Sponsored Program
SBIR
Awarding Agency
NIH : NIAID
Total Award Amount
$394,607
Award Phase
2
Solicitation Topic Code
855
Principal Investigator
Lisa Herron-Olson

Company Information

Syntiron LLC

1000 Westgate Drive Suite 109
Saint Paul, MN 55114
   (651) 641-2833
   info@syntiron.com
   www.syntiron.com
Location: Single
Congr. District: 04
County: Ramsey

Phase I

Contract Number: 1R43AI071545-01A2
Start Date: 5/15/2008    Completed: 4/30/2010
Phase I year
2008
Phase I Amount
$185,787
Staphylococcus aureus causes a variety of severe human diseases, including septicemia, pneumonia and endocarditis. Its considerable pathogenic potential results from an extensive virulence factor repertoire. The particularly high incidence of antibiotic resistance among human isolates and the potential use of staphylococcal superantigens as bioweapons further highlight the urgent need for developing effective methods for the prevention and control of this ubiquitous pathogen. Preliminary studies and previous investigations have demonstrated that proteins derived from S. aureus grown under iron-restricted conditions provide cross-protection against challenge by multiple strains of S. aureus. These results led to the hypothesis that one or more proteins present in the S. aureus iron-regulated protein-enriched composition after growth under iron-restriction are effective protective antigens. To test this hypothesis, and work toward the overall goal of developing safe and effective therapies to protect against S. aureus infection, Phase I feasibility studies with three specific aims are proposed: in Aim 1 we propose to separate and identify the immunoreactive proteins derived from S. aureus grown under iron-restricted conditions. During Aim 2, individual proteins will be generated and tested for their ability to stimulate specific antibody and cytokine responses in mice. Finally, in Aim 3, the recombinant proteins will be formulated into vaccines and tested for their ability to protect against S. aureus challenge in murine models of systemic and superficial infection. Taken together, these investigations will aid in determining 1) which of the proteins in the IRPE fraction provide protection against S. aureus challenge, and 2) the type of immune responses elicited by the vaccine components. These proposed Phase I feasibility studies will provide sufficient data for the formulation of rational strategies for developing safe and effective vaccines and immunotherapeutic agents against S. aureus infection.

Public Health Relevance:
This Public Health Relevance is not available.

Thesaurus Terms:
There Are No Thesaurus Terms On File For This Project.

Phase II

Contract Number: 5R43AI071545-02
Start Date: 5/15/2008    Completed: 4/30/2010
Phase II year
2009
Phase II Amount
$208,820
Staphylococcus aureus causes a variety of severe human diseases, including septicemia, pneumonia and endocarditis. Its considerable pathogenic potential results from an extensive virulence factor repertoire. The particularly high incidence of antibiotic resistance among human isolates and the potential use of staphylococcal superantigens as bioweapons further highlight the urgent need for developing effective methods for the prevention and control of this ubiquitous pathogen. Preliminary studies and previous investigations have demonstrated that proteins derived from S. aureus grown under iron-restricted conditions provide cross-protection against challenge by multiple strains of S. aureus. These results led to the hypothesis that one or more proteins present in the S. aureus iron-regulated protein-enriched composition after growth under iron-restriction are effective protective antigens. To test this hypothesis, and work toward the overall goal of developing safe and effective therapies to protect against S. aureus infection, Phase I feasibility studies with three specific aims are proposed: in Aim 1 we propose to separate and identify the immunoreactive proteins derived from S. aureus grown under iron-restricted conditions. During Aim 2, individual proteins will be generated and tested for their ability to stimulate specific antibody and cytokine responses in mice. Finally, in Aim 3, the recombinant proteins will be formulated into vaccines and tested for their ability to protect against S. aureus challenge in murine models of systemic and superficial infection. Taken together, these investigations will aid in determining 1) which of the proteins in the IRPE fraction provide protection against S. aureus challenge, and 2) the type of immune responses elicited by the vaccine components. These proposed Phase I feasibility studies will provide sufficient data for the formulation of rational strategies for developing safe and effective vaccines and immunotherapeutic agents against S. aureus infection.

Public Health Relevance:
This Public Health Relevance is not available.

Thesaurus Terms:
There Are No Thesaurus Terms On File For This Project.